In glioblastoma, a series of analogs of KHS101 have been shown to have significant anti-tumor cell proliferation activity by inhibiting TACC3 functions and are expected to be developed for the treatment of glioblastoma [42]. The gene discussed is TACC3; the disease is neoplasm.